Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Severe case 93% Improvement Relative Risk c19early.org/d Pande et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 209 patients in India (October 2020 - October 2021) Lower severe cases with higher vitamin D levels (p<0.000001) Pande et al., J. Communicable Diseases, doi:10.24321/0019.5138.202227 Favors vitamin D Favors control
Vitamin D Levels and its Association with Inflammatory Markers, Severity and Outcome in Hospitalised COVID-19 Patients - An Indian Perspective
Pande et al., Journal of Communicable Diseases, doi:10.24321/0019.5138.202227
Pande et al., Vitamin D Levels and its Association with Inflammatory Markers, Severity and Outcome in Hospitalised COVID-19.., Journal of Communicable Diseases, doi:10.24321/0019.5138.202227
Mar 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 209 hospitalized patients in India, showing vitamin D deficiency associated with COVID-19 severity. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of severe case, 93.4% lower, RR 0.07, p < 0.001, high D levels (≥20ng/ml) 7 of 116 (6.0%), low D levels (<20ng/ml) 85 of 93 (91.4%), NNT 1.2.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pande et al., 16 Mar 2022, retrospective, India, peer-reviewed, 7 authors, study period October 2020 - October 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Journal of Communicable Diseases Special Issue - COVID-19 & Other Communicable Diseases, Pg. No. 171-176 Peer Reviewed & Open Access Journal Research Article Vitamin D Levels and its Association with Inflammatory Markers, Severity and Outcome in Hospitalised COVID-19 Patients - An Indian Perspective Rajat Pande1, K Mayilananthi2, V Vrinda3, Rehab Yasir Nainar4, Bharanidharan G5, Ragalikhith K6, Durga Krishnan7 Postgraduate, 2,7Professor, 3Assistant Professor, 5Senior Resident, Department of General Medicine, Chettinad Hospital and Research Institute, Chennai, Tamil Nadu, India. DOI: https://doi.org/10.24321/0019.5138.202227 1,4,6 I N F O A B S T R A C T Corresponding Author: Durga Krishnan, Department of General Medicine, Chettinad Hospital and Research Institute, Chennai, Tamil Nadu, India. E-mail Id: drdurga79@gmail.com Orcid Id: https://orcid.org/0000-0003-0249-5097 How to cite this article: Pande R, Mayilananthi K, Vrinda V, Nainar RY, Bharanidharan G, Ragalikhith K, Krishnan D. Vitamin D Levels and its Association with Inflammatory Markers, Severity and Outcome in Hospitalised COVID-19 Patients - An Indian Perspective. Special Issue - COVID-19 & Other Communicable Disease. 2022;171-176. Background: The recent COVID-19 pandemic has taken over the world in enormous proportions like none other in recent times. Vitamin D plays an essential role in the immune system and has proven to have importance in the context of many respiratory infections. This study aims to unveil the possible correlation between vitamin D levels and disease outcome and affirm the role of hypovitaminosis D as an independent risk factor for severity in COVID 19. Date of Submission: 2021-10-29 Date of Acceptance: 2022-01-08 Methods: We studied 209 RTPCR confirmed COVID 19 positive cases. Serum 25(OH) D levels were done at the time of admission. HRCT chest and inflammatory markers (serum ferritin, D dimer, IL6 and CRP) were estimated on admission and repeated on case-to-case basis. Results: Out of 209 patients studied, 44.49% had vitamin D deficiency, 24.40% had Vitamin D insufficiency, and 31.11% had normal Vitamin D levels. Vitamin D deficiency significantly increased with advancing age. The mean vitamin D level in our study is 27.47 ± 21.86. 27.8% had mild COVID-19 disease as evidenced by HRCT imaging, 21.1% showed moderate disease, and 51.2% showed severe COVID-19. The mean values of inflammatory markers in Vitamin D deficient patients were as follows: D dimer (3298.88 ± 2230.14), Serum Ferritin (530.88 ± 497.14) CRP (175.34 ± 87.27) IL6 (125.39 ± 275.72). Significant correlation of Vitamin D with C reactive protein (r = -0.18, p ≤ 0.05), D-Dimer (r = -0.42, p < 0.0001), and CT severity score (r = -0.24, p ≤ 0.0001) was noted. Conclusion: In our study, Vitamin D inversely proportional levels were inversely proportional to CRP, D-Dimer, and CT severity. Keywords: Vitamin D, COVID19, Inflammatory Markers Journal of Communicable Diseases (P-ISSN: 0019-5138 & E-ISSN: 2581-351X) Copyright (c) 2022: Author(s). Published by Advanced Research Publications Pande R et al. Special Issue - COVID-19 & Other Communicable Disease. 2022
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit